HARMONi-2, with ivonescimab monotherapy versus pembrolizumab monotherapy, to be presented at the Presidential Symposium at WCLC 2024 Page 1

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we” or the “Company”) today announced that the primary analysis from the Phase III HARMONi-2 study of its novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented as part of the Presidential Symposium at the International Association for the Study of Lung Cancer’s (IASLC) 2024 World Conference on Lung Cancer (WCLC 2024) in San Diego, California. The presentation will take place on Sunday, September 8, 2024 at 8:37 a.m. PT (11:37 a.m. ET).

HARMONi-2 evaluated ivonescimab monotherapy versus pembrolizumab monotherapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors express positive PD-L1 (PD-L1 TPS >1%). HARMONi-2 is a single region, multi-center, double-blind Phase III study conducted in China sponsored by our collaboration partner, Akeso, Inc. (Akeso, HKEX code: 9926.HK), with data generated and analyzed by Akeso.